Atomoxetine (ATM) is a potent norepinephrine (NE) uptake inhibitor and increases both NE
and dopamine synaptic levels in prefrontal cortex, where it is thought to exert its beneficial …

Atomoxetine is a selective inhibitor of norepinephrine transporters and is currently being
used in the pharmacotherapy of attention deficit/hyperactivity disorder (ADHD). We have …

Atomoxetine has been approved by the FDA as the first new drug in 30 years for the
treatment of attention deficit/hyperactivity disorder (ADHD). As a selective norepinephrine …

The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called
tomoxetine or LY139603) has been shown to alleviate symptoms in Attention …

Background The majority of studies assessing executive function in attention deficit disorder
(ADD) have shown deficits in attentional set shifting using either the Wisconsin card sorting …

BACKGROUND: Atomoxetine, a highly selective noradrenaline reuptake inhibitor (SNRI),
shows efficacy in the treatment of attention-deficit/hyperactivity disorder (ADHD). Compared …

Atomoxetine (Strattera™) is a selective norepinephrine reuptake inhibitor and nonstimulant
that has shown greater efficacy than placebo in attention deficit hyperactivity disorder …

BACKGROUND: Atomoxetine, a selective noradrenaline reuptake inhibitor (SNRI) licensed
for the treatment of attention-deficit/hyperactivity disorder (ADHD), has been shown to …

Background and purpose: There is increasing evidence that not only the monoaminergic but
also the glutamatergic system is involved in the pathophysiology of attention‐deficit …

Attention-deficit/hyperactivity disorder (ADHD) is the most frequently diagnosed
neurodevelopmental disorder. The norepinephrine transporter (NET) inhibitor atomoxetine …